A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Clinical trial NCT05623020 · RECRUITING

Trial details

NCT number: NCT05623020
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2022-11-10
Primary completion: 2030-10-18
Enrollment: 1116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.